5-Amino-1MQ
NNMT inhibitor for fat cell shrinkage and metabolic activation.
75 mg/day
Key Benefits
blocks the enzyme that promotes fat storage in adipose tissue
raises intracellular NAD+ to activate SIRT1 and AMPK
shown to reduce fat cell size by 30–40% in research models
active via oral route in preclinical studies
Recommended Injection Sites
Optimal injection locations for 5-Amino-1MQ based on its route (Oral (capsule) or research solution) and pharmacokinetic profile.
Tap a glowing zone on the body map to highlight the matching site card — or tap a card to activate the zone.
Tap a zone to inject
Oral administration only.
- Injection not applicable — oral compound
Active Signaling Pathway
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 30 capsules vial — and when to plan your next order.
Actual duration may vary based on your specific protocol. Always consult your research guidelines for precise dosing schedules.
Scientific Background
Mechanism of Action
NNMT consumes SAM (S-adenosylmethionine) and NAD+ precursors in adipocytes, creating a metabolic sink that promotes fat storage. 5-Amino-1MQ blocks NNMT, restoring NAD+ availability, activating SIRT1/AMPK pathways, and shifting adipocytes toward a metabolically active, lipolytic state.
Clinical Context
5-Amino-1MQ represents a novel mechanism for metabolic intervention — targeting the epigenetic regulation of fat cell metabolism rather than appetite or absorption.
Research Highlights
- Shown to reduce adipocyte size by 30–40% in cell culture models
- Demonstrated significant fat mass reduction in diet-induced obese mice without caloric restriction
- Raises intracellular NAD+ levels — synergistic with NAD+ precursor supplementation
- Oral bioavailability demonstrated in preclinical pharmacokinetic studies
Storage & Reconstitution
Oral administration demonstrated in preclinical studies. Typical research cycle: 8–12 weeks.